Core Insights - Transcenta Therapeutics has appointed Dr. Christopher Hwang as Head of Global Partnerships for its Highly Intensified Continuous Bioprocessing (HiCB) platform, aiming to enhance its global technology out-licensing strategy [1][2] Company Overview - Transcenta Therapeutics is a global clinical stage biopharmaceutical company specializing in antibody-based therapeutics, with integrated capabilities in discovery, research, development, and manufacturing [6] - The company has established a global footprint with headquarters in Suzhou, a manufacturing facility in Hangzhou, and clinical development centers in China, the U.S., and Europe [7] Leadership and Expertise - Dr. Hwang holds a PhD in Biochemical Engineering from MIT and has over 30 years of experience in biopharmaceutical CMC, technology development, and manufacturing [2] - He has previously held leadership roles at Genzyme and Sanofi and was instrumental in building Transcenta's HiCB platform [2] HiCB Platform - The HiCB platform integrates intensified continuous perfusion upstream processing with hybrid continuous downstream purification, achieving a 10–15 fold increase in productivity compared to conventional fed-batch processes [3] - It reduces the cost of goods by at least 50%, lowers capital investment, and enables agile, just-in-time production [3] Strategic Collaborations - In late 2025, Transcenta executed a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., granting them a non-exclusive license to the HiCB platform along with comprehensive process documentation and regulatory support [4] - The company is expanding its global partner network through additional non-exclusive licensing agreements to enhance efficiency, lower costs, and increase manufacturing flexibility [5] R&D Pipeline - Proceeds from collaborations are reinvested to strengthen Transcenta's technology platform and advance its R&D pipeline for next-generation, best-in-class therapeutics [5]